cetuximab + mitoxantrone

Cetuximab + mitoxantrone is a combination therapy consisting of two distinct drugs: cetuximab, a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR) to inhibit cell proliferation and survival in EGFR-expressing tumor cells, and mitoxantrone, an anthracenedione antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, thereby preventing DNA replication and repair and inducing apoptosis in rapidly dividing cells. There are no known unique branded formulations of this specific combination, and no direct clinical guidelines or large studies describe the dual use of cetuximab and mitoxantrone together in a single regimen.